NCT07377747 Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
| NCT ID | NCT07377747 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Australia and New Zealand Sarcoma Association |
| Condition | Retroperitoneal Liposarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-05 |
| Primary Completion | 2032-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-09-05 with a primary completion date of 2032-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.
Eligibility Criteria
Inclusion Criteria: 1. Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection) 2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease 3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only 4. Sarcoma not originating from bone or abdominal or gynecological viscera 5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting) 6. WHO performance status 0-2 7. American Society of Anaesthesiologist (ASA) score 1-3 8. No prior RT for the retroperitoneal liposarcoma 9. Prior systemic therapy is allowed 10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease) 11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment 12. Patient deemed able to comply with study requirements according to investigator evaluation 13. Signed, IRB-approved written informed consent Exclusion Criteria: 1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team 2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible 3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease 4. Myxoid liposarcoma histology 5. Pregnancy
Contact & Investigator
Angela Hong
PRINCIPAL INVESTIGATOR
Chris O'Brien Lifehouse
Frequently Asked Questions
Who can join the NCT07377747 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Retroperitoneal Liposarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07377747 currently recruiting?
Yes, NCT07377747 is actively recruiting participants. Contact the research team at janina.chapman@petermac.org for enrollment information.
Where is the NCT07377747 trial being conducted?
This trial is being conducted at Atlanta, United States, Boston, United States, Columbus, United States, Houston, United States and 9 additional locations.
Who is sponsoring the NCT07377747 clinical trial?
NCT07377747 is sponsored by Australia and New Zealand Sarcoma Association. The principal investigator is Angela Hong at Chris O'Brien Lifehouse. The trial plans to enroll 100 participants.